Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean aromatase inhibitor?
Displaying drugs 76 - 100 of 2428 in total

Osilodrostat

Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's...
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT1 inhibitors ... OCT2 Inhibitors ... MATE 1 Inhibitors ... Cortisol Synthesis Inhibitors …

Amoxapine

Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation....
Approved
Matched Description: … TCAs are potent inhibitors of serotonin and norepinephrine reuptake. …
Matched Categories: … Adrenergic Uptake Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Neurotransmitter Uptake Inhibitors …

Buspirone

Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does...
Approved
Investigational
Matched Description: … used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors …
Matched Categories: … P-glycoprotein inhibitors …

Infigratinib

Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a...
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT1 inhibitors ... OCT2 Inhibitors ... BCRP/ABCG2 Inhibitors ... MATE 1 Inhibitors …

Avapritinib

Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a...
Approved
Investigational
Matched Categories: … MATE inhibitors ... BCRP/ABCG2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... BSEP/ABCB11 Inhibitors …

Crisaborole

Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Categories: … Phosphodiesterase Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Phosphodiesterase 4 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …

Resmetirom

Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... BSEP/ABCB11 Inhibitors ... UGT1A4 Inhibitors ... UGT1A9 Inhibitors ... OATP1B3 inhibitors …

Berotralstat

Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to...
Approved
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... Kallikrein Inhibitors ... P-glycoprotein inhibitors ... Serine Protease Inhibitors …

Ketoconazole

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... UGT1A1 Inhibitors ... UGT2B7 Inhibitors ... BSEP/ABCB11 Inhibitors ... 14-alpha Demethylase Inhibitors …

Novobiocin

Novobiocin is an antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964...
Approved
Investigational
Vet approved
Withdrawn
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... OATP1B3 inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors …

Ethambutol

Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …

Cimetidine

A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT1 inhibitors ... OCT2 Inhibitors ... BSEP/ABCB11 Inhibitors ... Enzyme Inhibitors …

Methimazole

Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …

Fexinidazole

Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focussed control efforts. Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first...
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... OATP1B3 inhibitors …

Viloxazine

Viloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. In the US,...
Approved
Investigational
Withdrawn
Matched Categories: … MATE inhibitors ... MATE 1 Inhibitors ... Adrenergic Uptake Inhibitors ... Monoamine Oxidase Inhibitors ... Monoamine Oxidase A Inhibitors …

Curcumin

Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …

Ubrogepant

Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Categories: … OCT2 Inhibitors ... UGT1A1 Inhibitors ... OATP1B3 inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …

Regorafenib

Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... UGT1A1 Inhibitors ... UGT1A9 Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors …

Oxymetholone

Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth in malnourished or underdeveloped patients. Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes....
Approved
Illicit
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors ... Cytochrome P-450 CYP3A7 Inhibitors …

Tezacaftor

Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... OCT2 Inhibitors ... OATP1B3 inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors …

Rimegepant

Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT2 Inhibitors ... MATE 1 Inhibitors ... OATP1B3 inhibitors ... OAT3/SLC22A8 Inhibitors …

Zafirlukast

Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once...
Approved
Investigational
Matched Categories: … NTCP Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …

Bivalirudin

Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... Thrombin Inhibitors ... Serine Protease Inhibitors …

Fluconazole

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... 14-alpha Demethylase Inhibitors ... P-glycoprotein inhibitors ... Steroid Synthesis Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …

Nilotinib

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... UGT1A1 Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors …
Displaying drugs 76 - 100 of 2428 in total